Search Results - "Tsuduki, Takao"

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study) by Nakasya, Akio, Hagiwara, Yuya, Ikoma, Tatsuki, Kurioka, Yusuke, Matsumoto, Toshihiko, Yamamoto, Yoshiyuki, Tsuduki, Takao, Kajiwara, Takeshi, Moriwaki, Toshikazu, Nishina, Tomohiro, Yamashita, Natsumi, Hyodo, Ichinosuke

“…Background Paclitaxel plus ramucirumab (PTX + RAM) is the standard second-line chemotherapy for unresectable advanced or recurrent gastric cancer (AGC)…”
Get full text

Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab by Matsumoto, Toshihiko, Ikoma, Tatsuki, Yamamura, Shogo, Miura, Kou, Tsuduki, Takao, Watanabe, Takanori, Nagai, Hiroki, Takatani, Masahiro, Yasui, Hisateru

Get full text

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab by Matsumoto, Toshihiko, Ikoma, Tatsuki, Yamamura, Shogo, Miura, Kou, Tsuduki, Takao, Watanabe, Takanori, Nagai, Hiroki, Takatani, Masahiro, Yasui, Hisateru

“…Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC). Recently, trifluridine/tipiracil (TFTD) plus bevacizumab also showed…”
Get full text

Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses by Matsumoto, Toshihiko, Yamamoto, Yosuke, Kuriona, Yusuke, Okazaki, Ukyo, Kimura, Shogo, Miura, Kou, Tsuduki, Takao, Watanabe, Takanori, Mastumoto, Yusuke, Takatani, Masahiro

“…Nivolumab has changed the treatment of advanced gastric cancer (AGC). Nivolumab shows better outcomes compared to best supportive care among AGC patients who…”
Get full text

Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study by Matsumoto, Toshihiko, Yamamura, Shogo, Ikoma, Tatsuki, Kurioka, Yusuke, Doi, Keitaro, Yasuda, Tomoyo, Boku, Shogen, Kawai, Takashi, Shibata, Nobuhiro, Nagai, Hiroki, Tsuduki, Takao, Shimada, Takanobu, Matsumoto, Yusuke, Tsumura, Takehiko, Takatani, Masahiro, Yasui, Hisateru, Satake, Hironaga

“…Background: A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is…”
Get full text

Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study by Hagiwara, Yuya, Nakasya, Akio, Matsumoto, Toshihiko, Ikoma, Tatsuki, Yamamoto, Yoshiyuki, Kurioka, Yusuke, Tsuduki, Takao, Kajiwara, Takeshi, Nishina, Tomohiro, Yamashita, Natsumi, Moriwaki, Toshikazu, Hyodo, Ichinosuke

“…Paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab (PTX/nab-PTX + RAM) is widely used as second-line chemotherapy for advanced…”
Get full text

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study by Matsumoto, Toshihiko, Yamamura, Shogo, Ikoma, Tatsuki, Kurioka, Yusuke, Doi, Keitaro, Boku, Shogen, Shibata, Nobuhiro, Nagai, Hiroki, Shimada, Takanobu, Tsuduki, Takao, Tsumura, Takehiko, Takatani, Masahiro, Yasui, Hisateru, Satake, Hironaga

“…Trastuzumab deruxtecan (T-DXd) has shown promising efficacy against positive advanced gastric cancer (AGC). However, data on its real-world efficacy in AGC…”
Get full text

Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab by Matsumoto, Toshihiko, Oda, Takashi, Yoshida, Yu, Kimura, Shogo, Himei, Hitomi, Tsuduki, Takao, Takagi, Shinjiro, Takatani, Masahiro, Morishita, Hirofumi

“…Takotsubo cardiomyopathy (TCM) is also known as stress-induced cardiomyopathy. The occurrence of TCM due to infusion reaction is extremely rare. A 65-year-old…”
Get full text

Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: A randomized clinical trial in third- or further-line treatment of gastric cancer by Kawabata, Ryohei, Sakai, Daisuke, Kadowaki, Shigenori, Tsuduki, Takao, Suzuki, Takahisa, Masuzawa, Toru, Shimozaki, Keitaro, Tsuda, Masahiro, Yamada, Takeshi, Yamaguchi, Toshifumi, Ueda, Shugo, Kito, Yosuke, Hirose, Toshiharu, Kawase, Tomono, Nomura, Takashi, Nishikawa, Kazuhiro, Kawakami, Hisato, Shimokawa, Toshio, Boku, Narikazu, Satoh, Taroh

“…339 Background: To confirm synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment, we evaluated the effect of pretreatment…”
Get full text

FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure by Matsumoto, Toshihiko, Kurioka, Yusuke, Okazaki, Ukyo, Matsuo, Yu, Kimura, Shogo, Miura, Kou, Tsuduki, Takao, Takagi, Shinjiro, Takatani, Masahiro, Morishita, Hirofumi

“…There is no standard chemotherapy for advanced pancreatic cancer (APC) after gemcitabine plus nab-paclitaxel (GP) failure. The aim of this study was to…”
Get full text

P2-055FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis by Matsumoto, Toshihiko, Kimura, Shogo, Himei, Hitomi, Okazaki, Ukyo, Kurioka, Yusuke, Tsuduki, Takao, Takagi, Shijiro, Takatani, Masahiro, Hiramatsu, Ysushi, Morishita, Hirofumi

“…Abstract Background Although, FOLFIRINOX and nab-paclitaxel plus gemcitabine showed survival benefit in patients with advanced pancreatic cancer (APC) , there…”
Get full text

P1-025Nivolumab for poor performance status patients : retrospective analysis by Matsumoto, Toshihiko, Kimura, Shogo, Himei, Hitomi, Okazaki, Ukyo, Kurioka, Yusuke, Tsuduki, Takao, Takagi, Shijiro, Takatani, Masahiro, Watanabe, Takanori, Morishita, Hirofumi

“…Abstract Objective Nivolumab has changed the treatment of advanced gastric cancer (AGC). Nivolumab shows better outcome compared to best supportive care in AGC…”
Get full text

FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis by Matsumoto, Toshihiko, Kimura, Shogo, Himei, Hitomi, Okazaki, Ukyo, Kurioka, Yusuke, Tsuduki, Takao, Takagi, Shijiro, Takatani, Masahiro, Hiramatsu, Ysushi, Morishita, Hirofumi

Get full text

Nivolumab for poor performance status patients : retrospective analysis by Matsumoto, Toshihiko, Kimura, Shogo, Himei, Hitomi, Okazaki, Ukyo, Kurioka, Yusuke, Tsuduki, Takao, Takagi, Shijiro, Takatani, Masahiro, Watanabe, Takanori, Morishita, Hirofumi

Get full text

A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G by Matsumoto, Toshihiko, Yamamoto, Yoshiyuki, Kotaka, Masahito, Masuishi, Toshiki, Tsuji, Yasushi, Shoji, Hirokazu, Hirata, Kenro, Tsuduki, Takao, Makiyama, Akitaka, Izawa, Naoki, Takahashi, Naoki, Tsuda, Masahiro, Yasui, Hisateru, Ohta, Takashi, Kito, Yosuke, Otsu, Satoshi, Hironaka, Shuichi, Yamazaki, Kentaro, Boku, Narikazu, Hyodo, Ichinosuke, Yoshimura, Kenichi, Muro, Kei

“…Background Non-inferiority of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) to irinotecan/fluoropyrimidine plus BEV in metastatic colorectal cancer…”
Get full text

Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab by Matsumoto, Toshihiko, Oda, Takashi, Yoshida, Yu, Kimura, Shogo, Himei, Hitomi, Tsuduki, Takao, Takagi, Shinjiro, Takatani, Masahiro, Morishita, Hirofumi

Get full text